{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:04:12Z","timestamp":1786993452787,"version":"build-2736575974"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Saudi Pharmaceutical Journal"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.jsps.2020.05.004","type":"journal-article","created":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T12:18:39Z","timestamp":1589545119000},"page":"771-778","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Awareness among patient at risk of developing Medication Related Osteonecrosis of the Jaw (MRONJ) \u2013 A primary prevention strategy"],"prefix":"10.1007","volume":"28","author":[{"given":"Abdulrhman","family":"Al Abdullateef","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhanad S.","family":"Alhareky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"10.1016\/j.jsps.2020.05.004_b0005","article-title":"Current controversies in classification, management, and prevention of bisphosphonate-related osteonecrosis of the jaw","volume":"565743","author":"Ascani","year":"2014","journal-title":"Int. J. Dentistry"},{"key":"10.1016\/j.jsps.2020.05.004_b0010","doi-asserted-by":"crossref","unstructured":"Aghaloo, TL., Felsenfeld, AL., Tetradis, S., 2010. Osteonecrosis of the jaw in a patient on Denosumab. J. Oral Maxillofac. Surg. 68, 959\u2013963. http:\/\/doi:10.1016\/j.joms.2009.10.010.","DOI":"10.1016\/j.joms.2009.10.010"},{"issue":"6","key":"10.1016\/j.jsps.2020.05.004_b0015","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.joms.2014.12.040","article-title":"Knowledge, practices, and opinions of ontario dentists when treating patients receiving bisphosphonates","volume":"73","author":"Alhussain","year":"2015","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.jsps.2020.05.004_b0020","first-page":"830","article-title":"Physicians' awareness of bisphosphonates-related osteonecrosis of the jaw","volume":"32","author":"Al-Mohaya","year":"2011","journal-title":"Saudi Med. J."},{"key":"10.1016\/j.jsps.2020.05.004_b0025","doi-asserted-by":"crossref","unstructured":"American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate Related Osteonecrosis of the Jaws, 2007. J. Oral Maxillofac. Surg. 3, 65,369-376. http:\/\/doi:10.1016\/j.joms.2006.11.003.","DOI":"10.1016\/j.joms.2006.11.003"},{"key":"10.1016\/j.jsps.2020.05.004_b0030","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jcms.2011.04.011","article-title":"Awareness and education of patients receiving bisphosphonates","volume":"40","author":"Bauer","year":"2012","journal-title":"J. Craniomaxillofac. Surg."},{"key":"10.1016\/j.jsps.2020.05.004_b0035","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00774-014-0566-x","article-title":"Prospective, mono-institutional study of the impact of a systematic prevention program on incidence and outcome of osteonecrosis of the jaw in patients treated with bisphosphonates for bone metastases","volume":"33","author":"Bramati","year":"2015","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.jsps.2020.05.004_b0040","first-page":"\/\/","article-title":"Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to anti-resorptive agents","volume":"10, 257\u2013275.http","author":"Campisi","year":"2014","journal-title":"Future Oncol."},{"key":"10.1016\/j.jsps.2020.05.004_b0045","doi-asserted-by":"crossref","unstructured":"Campisi, G., Di Fede, O., Musciotto, A., et al., 2007. Bisphosphonate-related osteonecrosis of the jaw (BRONJ): dental management designs and issues in diagnosis. Ann. Oncol. 18, 168\u2013172. http:\/\/DOI:10.1093\/annonc\/mdm250.","DOI":"10.1093\/annonc\/mdm250"},{"key":"10.1016\/j.jsps.2020.05.004_b0050","doi-asserted-by":"crossref","unstructured":"Carey, J.J., Palomo, L., 2008., Bisphosphonates and osteonecrosis of the jaw: innocent association or significant risk? Cleve. Clin. J. Med. 75, 871\u2013879. http:\/\/doi:10.3949\/ccjm.75a.08014.","DOI":"10.3949\/ccjm.75a.08014"},{"key":"10.1016\/j.jsps.2020.05.004_b0055","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.bone.2011.01.014","article-title":"Pharmacology of bisphosphonates","volume":"49","author":"Cremers","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.jsps.2020.05.004_b0060","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdn554","article-title":"Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid","author":"Dimopoulos","year":"2009","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jsps.2020.05.004_b0065","doi-asserted-by":"crossref","unstructured":"Drake, M.T., Clarke, B.L., Khosla, S., 2008. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin. Proc. Sep .83 (9):1032\u20131045. http:\/\/doi:10.4065\/83.9.1032.","DOI":"10.4065\/83.9.1032"},{"key":"10.1016\/j.jsps.2020.05.004_b0070","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1007\/s00520-015-2649-1","article-title":"Bisphosphonate-related osteonecrosis of the jaw: awareness and level of knowledge of Lebanese physicians","volume":"23","author":"El Osta","year":"2015","journal-title":"Support Care Cancer."},{"key":"10.1016\/j.jsps.2020.05.004_b0075","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1200\/JCO.2007.15.5424","article-title":"Osteonecrosis of the jaw related to bevacizumab","volume":"26","author":"Estilo","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsps.2020.05.004_b0080","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.coms.2015.06.004","article-title":"The role of antiangiogenic therapy in the development of osteonecrosis of the jaw","volume":"27","author":"Fantasia","year":"2015","journal-title":"Oral Maxillofac. Surg. Clin. North Am."},{"key":"10.1016\/j.jsps.2020.05.004_b0085","doi-asserted-by":"crossref","unstructured":"Fraser, L.A., Adachi, J.D., 2009. Glucocorticoid-induced osteoporosis: treatment update and review. Ther. Adv. Musculoskelet. 1, 71\u201385. http:\/\/doi:10.1177\/1759720X09343729.","DOI":"10.1177\/1759720X09343729"},{"key":"10.1016\/j.jsps.2020.05.004_b0090","doi-asserted-by":"crossref","unstructured":"Fusco, V., Santini, D., Armento, G., Tonini, G., et al., 2016. Campisi G. Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology. Expert Opin Drug Saf. 3, 1\u201311. http:\/\/doi:10.1080\/14740338.2016.1177021.","DOI":"10.1080\/14740338.2016.1177021"},{"key":"10.1016\/j.jsps.2020.05.004_b0095","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/ijcp.12022","article-title":"Denosumab: mechanism of action and clinical outcomes","volume":"66","author":"Hanley","year":"2012","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.jsps.2020.05.004_b0100","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ctrv.2015.04.007","article-title":"Drug induced osteonecrosis of the jaw","volume":"41","author":"Hamadeh","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jsps.2020.05.004_b0105","doi-asserted-by":"crossref","unstructured":"Hellstein, J.W., Adler, R.A., Edwards, B., et al., 2011. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: Executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J. Am. Dental Assoc. 11\/\/ 2011; 142(11):1243\u20131251. http:\/\/doi:10.14219\/jada.archive.2011.0108.","DOI":"10.14219\/jada.archive.2011.0108"},{"key":"10.1016\/j.jsps.2020.05.004_b0110","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsps.2020.05.004_b0115","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.cyto.2014.10.025","article-title":"The effect of nitrogen containing bisphosphonates, zoledronate and alendronate, on the production of pro-angiogenic factors by osteoblastic cells","volume":"71","author":"Ishtiaq","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.jsps.2020.05.004_b0120","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1177\/0022034515572021","article-title":"Infection and medication-related osteonecrosis of the jaw","volume":"94","author":"Katsarelis","year":"2015","journal-title":"J. Dent. Res."},{"key":"10.1016\/j.jsps.2020.05.004_b0125","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jsps.2020.05.004_b0130","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J. Bone Miner. Res"},{"key":"10.1016\/j.jsps.2020.05.004_b0135","first-page":"115","article-title":"Oral bisphosphonate therapy and osteonecrosis of the jaw: what to tell the concerned patient","volume":"20","author":"Koka","year":"2007","journal-title":"Int. J. Prosthodont."},{"key":"10.1016\/j.jsps.2020.05.004_b0140","first-page":"419","article-title":"Atypical femoral fractures can happen even with short duration bisphosphonate treatment","volume":"79","author":"Kohli","year":"2015","journal-title":"Conn. Med."},{"key":"10.1016\/j.jsps.2020.05.004_b0145","article-title":"Bisphosphonate induced hypocalcemia - report of six cases and review of the literature","volume":"144","author":"Kreutle","year":"2014","journal-title":"Swiss Med. Wkly."},{"key":"10.1016\/j.jsps.2020.05.004_b0150","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s00520-008-0484-3","article-title":"Osteonecrosis of the jaw (ONJ) in cancer patients treated with Bisphosphonates: how the knowledge of a phenomenon can change its evolution","volume":"16","author":"La Verde","year":"2008","journal-title":"Support. Care Cancer."},{"key":"10.1016\/j.jsps.2020.05.004_b0155","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.bone.2013.10.002","article-title":"Clinical study evaluating the effect of bevacizumab on the severity of zoledronic acid-related osteonecrosis of the jaw in cancer patients","volume":"58","author":"Lescaille","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.jsps.2020.05.004_b0160","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/j.1365-2753.2009.01203.x","article-title":"Bisphosphonate-associated osteonecrosis of the jaw. Knowledge and attitudes of dentists and dental students: a preliminary study","volume":"16","author":"Lopez-Jornet","year":"2010","journal-title":"J. Eval. Clin. Pract."},{"key":"10.1016\/j.jsps.2020.05.004_b0165","doi-asserted-by":"crossref","DOI":"10.1111\/idh.12122","article-title":"Survey on awareness and perceptions of bisphos phonate-related osteonecrosis of the jaw in dental hygienists in Seoul","author":"Mah","year":"2015","journal-title":"Int. J. Dent. Hyg."},{"key":"10.1016\/j.jsps.2020.05.004_b0170","doi-asserted-by":"crossref","first-page":"562","DOI":"10.14219\/jada.archive.2010.0229","article-title":"How patients' lack of knowledge about oral bisphosphonates can interfere with medical and dental care","volume":"141","author":"Migliorati","year":"2010","journal-title":"J. Am. Dental Assoc."},{"key":"10.1016\/j.jsps.2020.05.004_b0175","doi-asserted-by":"crossref","unstructured":"Mirza, F., Canalis, E., Secondary osteoporosis: pathophysiology and management. European Journal of Endocrinology. 173, R131-R151. http:\/\/doi:10.1530\/EJE-15-0118.","DOI":"10.1530\/EJE-15-0118"},{"key":"10.1016\/j.jsps.2020.05.004_b0180","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2105\/AJPH.69.1.47","article-title":"Effects of written drug information on patient knowledge and compliance: a literature review","volume":"69","author":"Morris","year":"1979","journal-title":"Am. J. Public Health."},{"key":"10.1016\/j.jsps.2020.05.004_b0185","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s00063-009-1181-9","article-title":"Risks associated with drug therapy. What do patients need to know? What can they do?","volume":"104","author":"Mueller","year":"2009","journal-title":"Med. Klin. (Munich)."},{"key":"10.1016\/j.jsps.2020.05.004_b0190","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00228-003-0570-x","article-title":"Awareness of the side effects of possessed medications in a community setting","volume":"58","author":"Papanikolaou","year":"2003","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"377\u2013381","key":"10.1016\/j.jsps.2020.05.004_b0195","article-title":"Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Paul","year":"2009","journal-title":"J. Biomed. Inform."},{"key":"10.1016\/j.jsps.2020.05.004_b0200","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: a literature review and clinical practice guidelines","volume":"80","author":"Pickett","year":"2006","journal-title":"J. Dent. Hyg."},{"key":"10.1016\/j.jsps.2020.05.004_b0205","doi-asserted-by":"crossref","unstructured":"Ripamonti, C.I., Maniezzo, M., Campa, T., et al., 2009. Decreased occurrence of osteo necr -osis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann. Oncol. Jan 20, 137\u2013145. http:\/\/doi:10.1093\/annonc\/mdn526.","DOI":"10.1093\/annonc\/mdn526"},{"key":"10.1016\/j.jsps.2020.05.004_b0210","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u2013 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J. Oral Maxillofac. Surg"},{"issue":"1","key":"10.1016\/j.jsps.2020.05.004_b0215","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bone.2011.04.022","article-title":"Bisphosphonates: The first 40years","volume":"49","author":"Russell","year":"2011","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.jsps.2020.05.004_b0220","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/03009740151095385","article-title":"Do undereducated patients read and understand written education materials?","volume":"30","author":"Sava\u015f","year":"2001","journal-title":"Scand. J. Rheumatol."},{"issue":"555\u2013576","key":"10.1016\/j.jsps.2020.05.004_b0225","article-title":"Denosumab: a review of its use in postmenopausal women with oste -oporosis","volume":"31","author":"Scott","year":"2014","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jsps.2020.05.004_b0230","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1210\/jc.2015-1794","article-title":"Declining incidence of medication-related osteonecrosis of the jaw in patients with cancer","volume":"100","author":"Sim","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsps.2020.05.004_b0235","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4103\/2229-516X.112240","article-title":"Awareness about prescribed drugs among patients attending Out-patient departments","volume":"3","author":"Singh","year":"2013","journal-title":"Int. J. Appl. Basic Med. Res."},{"key":"10.1016\/j.jsps.2020.05.004_b0240","article-title":"Denosumab: a novel antiresorptive drug for osteo -porosis","volume":"82,105\u2013114","author":"Suresh","year":"2015","journal-title":"Cleve. Clin. J. Med."},{"issue":"1","key":"10.1016\/j.jsps.2020.05.004_b0245","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/annonc\/mdr039","article-title":"Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience","volume":"23","author":"Vandone","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jsps.2020.05.004_b0250","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1124\/dmd.108.021071","article-title":"Bio distribution and plasma protein binding of zoledronic acid","volume":"36","author":"Weiss","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jsps.2020.05.004_b0255","doi-asserted-by":"crossref","unstructured":"Yamazaki, T., Takahashi, K., Bessho, K., Recent clinical evidence in bisphosphonate-related osteomyelitis of the jaw: focus on risk, prevention and treatment. Rev. Recent Clin. Trials. 9, 37\u201352. http:\/\/doi:10.2174\/1574887109666140423120614.","DOI":"10.2174\/1574887109666140423120614"},{"key":"10.1016\/j.jsps.2020.05.004_b0260","doi-asserted-by":"crossref","unstructured":"Yoo, J.Y., Park, Y.D., Kwon, Y.D., et al., 2010. Survey of Korean dentists on the awareness on bisphosphonate-related osteonecrosis of the jaws. J. Investig. Clin. Dent. 1, 90\u201395. http:\/\/doi:10.1111\/j.2041-1626.2010.00024.x.","DOI":"10.1111\/j.2041-1626.2010.00024.x"},{"issue":"2","key":"10.1016\/j.jsps.2020.05.004_b0265","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/jbmr.2693","article-title":"Osteonecrosis of the jaw in the united states food and drug administration's adverse event reporting system (FAERS): DRUG INDUCED ONJ AND FAERS DATABASE","volume":"31","author":"Zhang","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jsps.2020.05.004_b0270","doi-asserted-by":"crossref","DOI":"10.1001\/archinte.161.5.706","article-title":"How much information about adverse effects of medication do patients want from physicians?","author":"Ziegler","year":"2001","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.jsps.2020.05.004_b0275","first-page":"2981","article-title":"Antineoplastic activity of zoledronic acid and denosumab","volume":"33","author":"Zwolak","year":"2013","journal-title":"Anticancer Res."}],"container-title":["Saudi Pharmaceutical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319016420301079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319016420301079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T12:24:37Z","timestamp":1736166277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1319016420301079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S1319016420301079"],"URL":"https:\/\/doi.org\/10.1016\/j.jsps.2020.05.004","relation":{},"ISSN":["1319-0164"],"issn-type":[{"value":"1319-0164","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Awareness among patient at risk of developing Medication Related Osteonecrosis of the Jaw (MRONJ) \u2013 A primary prevention strategy","name":"articletitle","label":"Article Title"},{"value":"Saudi Pharmaceutical Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsps.2020.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V. on behalf of King Saud University.","name":"copyright","label":"Copyright"}]}}